Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.
about
Stem cells as cellular vehicles for gene therapy against glioblastomaOverview of current immunotherapeutic strategies for gliomaGene therapy for brain tumors: basic developments and clinical implementationDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsHMGB1 mediates endogenous TLR2 activation and brain tumor regressionCombining cytotoxic and immune-mediated gene therapy to treat brain tumorsHuman gene therapy and imaging in neurological diseases.Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionHuman Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsMarmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyMagnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent.Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model.Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.Current status of gene therapy for brain tumors.Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human gliomaFms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain.Gene therapy and targeted toxins for glioma.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Recent developments on immunotherapy for brain cancer.Adenoviral-mediated gene transfer into the canine brain in vivo.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Genetic strategies for brain tumor therapy.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialEfficacy of nonviral gene transfer in the canine brain.Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaFlt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.
P2860
Q26771835-80176F53-3795-4788-A0B4-19A67012BF26Q26776345-6ACC2A4E-E7CA-4B62-B459-3AF2E670194CQ26829086-4FAF45B1-D488-45A8-BF33-DFF14B1EAC35Q27014829-96FE1F14-61AB-4EAA-870A-17FA9125F742Q27307459-615AD36E-79A7-443F-8EBA-35366EB48BF9Q31013320-FC982276-E5A2-4119-B927-3459D6CAA589Q31023442-4D452671-3DC9-456F-A84D-4833553C110DQ33330270-9F139448-964E-41F7-9223-56ABAB24A297Q33551268-CFEAC961-2747-45F0-AC33-34136EA2DF58Q33605719-7D7DBF3D-4333-44B2-A8F9-963225CAD7B3Q33828114-2DACA58B-2EE9-44C2-A576-ADC80C02C8D0Q33877450-674AC178-F366-4AB2-A299-BD026187FFF2Q33950709-81A866AF-60AC-4533-B5D0-690979FA0267Q34012284-09827CB2-D070-42BB-963B-6EBC9CA295BFQ34022048-039257C5-366B-4A0F-985D-81DFF8CB97BAQ34063140-F0615A76-8705-4351-8244-9F5831569430Q34069598-1A9AB9C9-7A0A-475A-A1EB-547CADFBA5CDQ34076034-BDD9A576-50A6-490A-8CD2-B4F8D7A56D34Q34198939-EB081E3B-F858-4F8D-90A8-7BFD0C3E2AD9Q34233124-5E35F546-8FBB-456B-8AF4-76FDE019F0A0Q34240433-9D3C127A-1E76-4EE1-8CE3-BDE10AF3D928Q34318157-5EA2FE56-2EEF-44B9-ADFF-4EABE92CDC79Q34647123-604AFDE3-3C84-4421-B483-03287AED6316Q34657329-018C5818-8879-457F-9C1A-E679CED11231Q35069546-F123351F-DFF3-4B81-80BD-7ED0E1720273Q35118933-71E85618-A779-4CE1-B459-11151488AC3BQ35285859-A69C59A8-C391-4BBD-B22F-02F9541120FDQ35527165-7F511573-3E5F-4BE2-A65E-4B1A44BCC31FQ35870480-3C9B2E6E-243B-4789-A913-08CA2C4FE9ACQ35992355-B8D59FE3-D5FD-4747-8210-EABD7C49D50BQ36172992-CFABC96B-82B0-4F61-8045-D686AF9B46D3Q36200438-AFC10FBE-015E-4F96-9E69-AE85F0196041Q36247099-2EB869AB-B6D9-4EF8-9465-83E7D05894F8Q36534329-9C15AC90-DCD5-4E46-A2B3-B4B1C3F1D221Q36658314-9E400164-5C79-40A8-8BA5-5D9D2C9C7173Q36658322-01E1E65C-7569-44B1-9AF8-F230615E79FCQ36811505-FA6CC37D-A44E-49A8-B993-2E4C2CBFEDD0Q36994063-10CA3BEB-9F1B-4899-B86E-584B6B3CD437Q37010979-C3547C0E-8149-4E25-B20E-66BACFCDAEACQ37079181-6F9408F8-43A4-43FC-962C-ED8687A41B31
P2860
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Inflammatory and anti-glioma e ...... tracranial glioma progression.
@ast
Inflammatory and anti-glioma e ...... tracranial glioma progression.
@en
Inflammatory and anti-glioma e ...... -like tyrosine kinase 3 ligand
@nl
type
label
Inflammatory and anti-glioma e ...... tracranial glioma progression.
@ast
Inflammatory and anti-glioma e ...... tracranial glioma progression.
@en
Inflammatory and anti-glioma e ...... -like tyrosine kinase 3 ligand
@nl
prefLabel
Inflammatory and anti-glioma e ...... tracranial glioma progression.
@ast
Inflammatory and anti-glioma e ...... tracranial glioma progression.
@en
Inflammatory and anti-glioma e ...... -like tyrosine kinase 3 ligand
@nl
P2093
P2860
P50
P1433
P1476
Inflammatory and anti-glioma e ...... ntracranial glioma progression
@en
P2093
Chunyan Liu
Gwendalyn D King
Jeffrey M Zirger
Mariana Puntel
Pedro R Lowenstein
Shyam Goverdhana
Weidong Xiong
P2860
P304
P356
10.1016/J.YMTHE.2004.08.025
P577
2004-12-01T00:00:00Z